RHYTHM PHARMACEUTICALS, INC. 4

Chief Scientific Officer Alastair Garfield sold a total of 7,763 shares of Rhythm Pharmaceuticals, Inc. common stock on August 13, 2026 at weighted average prices around $116–$119 per share under a Rule 10b5‑1 plan.

On August 13, 2026, Rhythm Pharmaceuticals, Inc. Chief Scientific Officer Alastair Garfield executed a series of open‑market sales of common stock pursuant to a pre‑arranged Rule 10b5‑1 trading plan, disposing of an aggregate 7,763 shares at weighted average prices between approximately $116.11 and $119.17 per share. The transactions were reported in four line items: 2,007 shares at $116.1093, 1,556 shares at $117.0759, 3,400 shares at $118.2843, and 800 shares at $119.1688, with each line reflecting multiple trades within the stated price ranges. Following these sales, Garfield’s directly held ownership decreased from 10,058 shares to 2,295 shares, leaving him with a significantly reduced but continuing equity stake in the issuer.

Filing Facts

CIK

1649904

Ticker

RYTM

Form

4

Source Type

fda

Accession

0001649904-26-000013

Alert Tier

6